Cordis’ Post

Learn from our esteemed investigators firsthand about their experiences with MYNX CONTROL™ VENOUS Vascular Closure Device (VCD) in the ReliaSeal Study. Watch the full video, now available on the Cordis VuMedi platform. https://lnkd.in/gFGavMd2 Sanjaya Gupta #CordisGoBeyond #MoveForwardWithMYNX #Venous #EP

In a recent Endovascular Today article, Ripal Gandhi, M.D., FSVM, FSIR, Nima Kokabi, MD FRCPC and Alex Villalobos, MD discuss #Y90 in practice. Here are some thoughts from Dr. Gandhi on our FLEXdose Delivery Program. Check out the full video here: https://lnkd.in/egndVp4S

When you need the benefits of a large system in a handheld device, turn to Dantec® Clavis™ for EMG/STIM-guided injections. This handheld EMG device offers simple, intuitive use for guidance for injection of medicinal products to help effectively treat conditions like strabismus, dystonia, and spasticity. Designed to provide the functionality of EMG recording and stimulation with mobility and simplicity, Clavis allows for accurate injection at the exact point of treatment to save time and support effective patient care. 🔗 Learn more about how Dantec Clavis can enhance your practice: https://hubs.li/Q02LgZy80 #EMG #neurodiagnostics #patientcare #EDX

Symptomatic focal atrial tachycardia. High-density mapping with HD-Grid reveals a broad activation front, suggesting the origin in the LAA-Apex. What would you do? Try to exactly localize the origin in the distal LAA with a linear RF-Catheter and ablate or LAA-Isolation with a single-shot device (e.g. Farapulse) with consecutive interventional LAA-Closure? #EPeeps #KlinikumIngolstadt Klinikum Ingolstadt

US HCPs: #MIDWAY 62 supporting FREDx deployment, telescoped Pipeline deployment, and balloon angioplasty for management of hypophyseal ICA aneurysm. Supported by #BMX81. Thank you for sharing Dr. Diaz! Rx only. Risk: peninc.info/risk Clinical results may vary

On Monday at #THT2024, BiVACOR® founder & CTO Daniel Timms presented our novel Total Artificial Heart (TAH). What is the BiVACOR TAH? 👇 The BiVACOR Total Artificial Heart is designed as the first long-term therapy dedicated to patients with severe biventricular heart failure. It is an implantable total artificial heart based on rotary blood pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of providing enough cardiac output to an adult male undergoing exercise. Using magnetic levitation (MAGLEV) technology, the same principle used in high-speed trains, the design includes left and right vanes positioned on a common rotor to form the only moving part, a magnetically suspended double-sided centrifugal impeller. Even though there are no valves or flexing ventricle chambers, the pulsatile outflow is made possible by rapidly cycling the rotational speed of the impeller. The non-contact suspension provides large blood gaps minimizing blood trauma and eliminating mechanical wear to offer a durable, reliable, and biocompatible heart replacement. View the slides from THT at TCTMD here: https://lnkd.in/e6FAx5bQ Please note that a free registration is required to view. #tht #tht24 #heartfailure #heartdisease #cardiology #medtech #healthtech #medicaldevices

Did you know Elekta linacs enable exquisite dose shaping for every patient, including large, complex, multi-target head and neck cases? They do this with dynamic jaw tracking, 1mm resolution across a 40x40 field and advanced interdigitation. Find out how ➡️ https://bit.ly/44NW9v9 #HeadandNeckCancerAwareness #radonc #hncsm

Reposting this insightful piece! 🌟 It's impressive how Elekta linacs enhance treatment precision, especially for complex head and neck cases. The technology truly makes a difference in patient care by enabling exquisite dose shaping tailored to individual needs. Check it out! #HeadandNeckCancerAwareness

Building on the exciting insights from #ESC2024, I’m proud to share a deeper review of the findings from the MATTERHORN, RESHAPE-HF2, and Tri.fr trials.    In the MATTERHORN and RESHAPE-HF2, Abbott’s #MitraClip Transcatheter Edge-to-Edge Repair (TEER) demonstrated remarkable safety and effectiveness for patients with secondary mitral regurgitation (SMR). Similarly, the Tri.Fr trial showed treating tricuspid regurgitation (TR) with a combination of #TriClip TEER and medical management leads to significant quality-of-life benefits.    Patients are at the heart of everything we do here at Abbott, and I’m grateful to see how these innovative devices continue to transform the treatment landscape offering new hope for people living with complex heart conditions. https://lnkd.in/gj6Vze8c Safety Info:   https://abbo.tt/MitraClip  https://lnkd.in/gQ_nksia     #TEER #Innovation #ClinicalTrial #AbbottProud

Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation